Columbia regulatory update

COB's Crinone natural progesterone product received marketing approval in Finland. Approved indications include the prevention of hyperplasia and endometrial cancer in postmenopausal women receiving hormone replacement therapy; in vitro fertilization procedures; reduction of premenstrual symptoms; menstrual irregularities; dysmenorrhea; dysfunctional uterine bleeding; and infertility due to inadequate progesterone production. ...